

Lifeline Drugs & Pharma Limited

Regd Office : 17, 3rd Floor, Zaveri Bhavan, 85/87, Old Hanuman Lane, Kalbadevi Road, Mumbai-400 002
CIN - L51900MH1982PLC028972, Email : lifelinedrugspharmaltd@gmail.com, Website : www.lifelinedrugsandpharmaltd.com

Statement of Audited Results for the Quarter & 12 months ended 31st March 2014

Rs. in Lacs

| Sr. No. | Particulars | 3 Months ended | Preceding 3 | Corresponding 3 | Year to date | Year to date |
|----------|--|-----------------|--|-----------------|-----------------|---------------|
| | | 31.03.2014 | Months ended | Months ended | figures as on | figures as on |
| | | Un-Audited | | | Audited | |
| 1 | Income from Operations | | | | | |
| | a) Net Sales/Income from Operations | 1,759.66 | 964.16 | - | 4,007.78 | - |
| | b) Other Operating Income | - | - | - | - | - |
| | Total Income from Operations (Net) | 1,759.66 | 964.16 | - | 4,007.78 | - |
| 2 | Expenses | | | | | |
| | (a) Cost of Material Consumed | - | - | - | - | - |
| | (b) Purchases of Stock-in-trade | 919.82 | 944.23 | - | 3,128.75 | - |
| | (c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade | 832.62 | - | - | 832.62 | - |
| | (d) Employees Benefit Expenses | 4.41 | 1.62 | 1.03 | 9.46 | 3.75 |
| | (e) Depreciation & Amortization Expenses | 0.10 | - | - | 0.10 | - |
| | (f) Other Expenditure | 8.47 | 3.75 | (3.78) | 16.14 | 4.51 |
| | Total Expenses | 1,765.42 | 949.60 | (2.75) | 3,987.07 | 8.26 |
| 3 | Profit/(Loss) from Operations before other income, finance cost and exceptional Expenses (1-2) | (5.76) | 14.56 | 2.75 | 20.71 | (8.26) |
| 4 | Other Income/(Loss) | 44.37 | 22.62 | 3.46 | 76.83 | 28.64 |
| 5 | Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4) | 38.61 | 37.18 | 6.21 | 97.54 | 20.38 |
| 6 | Finance Costs | - | - | - | - | - |
| 7 | Profit/(Loss) from ordinary activities after finance cost but before exceptional items (3-4) | 38.61 | 37.18 | 6.21 | 97.54 | 20.38 |
| 8 | Exceptional Items | - | - | - | - | - |
| 9 | Profit(+)/Loss(-) from ordinary activities before Tax (7-8) | 38.61 | 37.18 | 6.21 | 97.54 | 20.38 |
| 10 | Tax Expense | 32.05 | - | - | 32.05 | 6.30 |
| 11 | Net Profit (+)/Loss(-) from ordinary activities after tax (9-10) | 6.56 | 37.18 | 6.21 | 65.49 | 14.08 |
| 12 | Extra Ordinary Items (Net of Tax Expense of Rs. Lac) | - | - | - | - | - |
| 13 | Net Profit (+)/Loss(-) for the period (11-12) | 6.56 | 37.18 | 6.21 | 65.49 | 14.08 |
| 14 | Share of Profit/(Loss) of Associates* | - | - | - | - | - |
| 15 | Minority Interest* | - | - | - | - | - |
| 16 | Net Profit (+)/Loss(-) after tax, minority interest and Share of Profit / (Loss) of Associates (13-14-15) | 6.56 | 37.18 | 6.21 | 65.49 | 14.08 |
| 17 | Paid-up Equity Share Capital (Face Value of Rs. 1/- each) | 362.40 | 362.40 | 307.40 | 362.40 | 307.40 |
| 18 | Reserves excluding revaluation Reserves as per last Balance Sheet | - | - | - | 1,765.17 | 968.27 |
| 19 | Earning Per Share (before extra-ordinary items) of Rs. 1/- each (not annualized) | | | | | |
| | (i) a) Basic | 0.02 | 0.10 | 0.20 | 0.18 | 0.46 |
| | b) Diluted | 0.02 | 0.10 | 0.20 | 0.18 | 0.46 |
| 19 | Earning Per Share (after extra-ordinary items) of Rs. 1/- each (not annualized) | | | | | |
| | (ii) a) Basic | 0.02 | 0.10 | 0.20 | 0.18 | 0.46 |
| | b) Diluted | 0.02 | 0.10 | 0.20 | 0.18 | 0.46 |
| A | PARTICULARS OF SHAREHOLDING | | | | | |
| | Public Shareholding | | | | | |
| | - Number of Shares | 36,215,000 | 36,215,000 | 3,071,500 | 36,215,000 | 3,071,500 |
| | - Percentage of Share Holding | 99.93 | 99.93 | 99.92 | 99.93 | 99.92 |
| 18 | Promoter and Promoter Group Shareholding | | | | | |
| | a) Pledged/Encumbered | | | | | |
| | - Number of Shares | - | - | - | - | - |
| | - Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group) | - | - | - | - | - |
| | - Percentage of Shares (as a % of the total Share Capital of the Company) | - | - | - | - | - |
| | b) None-Encumbered | | | | | |
| | - Number of Shares | 25,000 | 25,000 | 2,500 | 25,000 | 2,500 |
| | - Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group) | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| | - Percentage of Shares (as a % of the total Share Capital of the Company) | 0.07 | 0.07 | 0.08 | 0.07 | 0.08 |
| B | INVESTOR COMPLAINTS | | | | | |
| | Pending at the beginning of the Quarter | - | Disposed during the Quarter | | - | - |
| | Received during the Quarter | - | Remaining Unresolved at the end of Quarter | | - | - |

Notes :

- Segmental Report for the Quarter as per AS-17 of ICAI is not applicable for the Quarter.
- Above results were reviewed by Audit Committee taken on record in Board Meeting held on May 27, 2014.
- The figures of last Quarter are the balancing figures between Audited figures in respect of full financial year and the published year to date figures upto the 3rd Quarter of the Current Financial Year.
- The Statutory Auditors of the Company have carried out Audit for the above Financial Results.

Place : Mumbai
Date : 27th May 2014

For Lifeline Drugs & Pharma Limited
S/d-
Alok Behera
Managing Director

Lifeline Drugs & Pharma Limited
Statement of Assets & Liabilities

Rs. in Lacs

| Particulars | | For the Year Ended | |
|-------------|---|--------------------|-----------------|
| | | 31-Mar-2014 | 31-Mar-2013 |
| | | Un-Audited | Audited |
| A | EQUITY & LIABILITIES | | |
| 1 | Shareholders' Fund | | |
| | (a) Share Capital | 362.40 | 307.40 |
| | (b) Reserves and Surplus | 1,765.17 | 968.27 |
| | (c) Money Received against Share Warrants | - | - |
| | Sub-Total - Share Holders Fund | 2,127.57 | 1,275.67 |
| 2 | Share Capital Money (Pending Allotment) | - | - |
| 3 | Minority Interest* | - | - |
| 4 | Non Current Liabilities | | |
| | (a) Long Term Borrowings | - | - |
| | (b) Deferred Tax Liabilities (Net) | 0.04 | - |
| | (c) Other Long Term Liabilities | - | - |
| | (d) Long Term Provisions | - | - |
| | Sub-Total - Long Term Liabilities | 0.04 | - |
| 5 | Current Liabilities | | |
| | (a) Short Term Borrowings | - | - |
| | (b) Trade Payables | 1,080.74 | - |
| | (c) Other Current Liabilities | 32.04 | - |
| | (d) Short Term Provisions | 38.69 | 21.72 |
| | Sub-Total - Current Liabilities | 1,151.47 | 21.72 |
| | TOTAL EQUITY & LIABILITIES | 3,279.08 | 1,297.39 |
| B | ASSETS | | |
| 1 | Non-Current Assets | | |
| | (a) Fixed Assets | 0.69 | - |
| | (b) Goodwill on Consolidation* | - | - |
| | (c) Non-Current Investments | - | - |
| | (d) Deferred Tax Assets (Net) | - | - |
| | (e) Long Term Loans & Advances | - | - |
| | (f) Other Non-Current Assets | - | - |
| | Sub-Total - Non Current Assets | 0.69 | - |
| 2 | Current Assets | | |
| | (a) Current Investments | - | - |
| | (b) Inventories | 7.71 | 840.33 |
| | (c) Trade Receivables | 971.52 | 169.57 |
| | (d) Cash & Cash Equivalents | 22.63 | 10.84 |
| | (e) Short Term Loans & Advances | 2,276.53 | 276.65 |
| | (f) Other Current Assets | - | - |
| | Sub-Total - Current Assets | 3,278.39 | 1,297.39 |
| | TOTAL - ASSETS | 3,279.08 | 1,297.39 |